| pubmed-article:9811349 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C0033262 | lld:lifeskim |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C1152199 | lld:lifeskim |
| pubmed-article:9811349 | lifeskim:mentions | umls-concept:C0450363 | lld:lifeskim |
| pubmed-article:9811349 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9811349 | pubmed:dateCreated | 1998-11-25 | lld:pubmed |
| pubmed-article:9811349 | pubmed:abstractText | Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is associated with angiogenesis and the progression of human ovarian cancer. The enzyme converts thymidine to thymine and 2'-deoxyribose-1-phosphate and can also metabolize the prodrug 5'-deoxy-5-fluorouridine (Furtulon) to 5-fluorouracil and 5'-deoxy-D-ribose-1-phosphate. The aim of this study was to obtain information about the activities of Furtulon in an established three-dimensional model of angiogenesis. The plan was to study partial and complete effects of Furtulon (in the absence and presence of PD-ECGF/TP or ovarian cancer cyst fluids) on the formation and destruction of microvessels from cultured segments of rat aorta in serum-free media. The endpoint was the number and form of microvessels compared with controls after 4, 7, 11, and 14 (and sometimes 17) days in culture. Furtulon (10 micromol/L) gradually reduced the size and number of microvessels over 17 days of culture (100 micromol/L significantly reduced the number by day 4). PD-ECGF/TP (10 ng/ml) and ovarian cancer cyst fluids (2% in medium, v/v) stimulated the production of microvessels. The culture of explants with Furtulon and PD-ECGF/TP or ovarian cancer cyst fluids (from day 1 or day 11 of culture) enhanced the vasoclastic activity of the drug. The effect of Furtulon at the highest dose (1000 micromol/L) or at a lower dose (100 micromol/L) in the presence of ovarian cancer cyst fluid was not reversible after culture day 11. | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9811349 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9811349 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9811349 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9811349 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:9811349 | pubmed:issn | 0002-9440 | lld:pubmed |
| pubmed-article:9811349 | pubmed:author | pubmed-author:MiyazakiKK | lld:pubmed |
| pubmed-article:9811349 | pubmed:author | pubmed-author:CollinsW PWP | lld:pubmed |
| pubmed-article:9811349 | pubmed:author | pubmed-author:FarzanehFF | lld:pubmed |
| pubmed-article:9811349 | pubmed:author | pubmed-author:HataKK | lld:pubmed |
| pubmed-article:9811349 | pubmed:author | pubmed-author:StevensonD... | lld:pubmed |
| pubmed-article:9811349 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9811349 | pubmed:volume | 153 | lld:pubmed |
| pubmed-article:9811349 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9811349 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9811349 | pubmed:pagination | 1573-8 | lld:pubmed |
| pubmed-article:9811349 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:meshHeading | pubmed-meshheading:9811349-... | lld:pubmed |
| pubmed-article:9811349 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9811349 | pubmed:articleTitle | Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer. | lld:pubmed |
| pubmed-article:9811349 | pubmed:affiliation | Department of Obstetrics and Gynaecology, King's College School of Medicine and Dentistry, London, United Kingdom. | lld:pubmed |
| pubmed-article:9811349 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9811349 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9811349 | lld:pubmed |
